Laurus Labs Ltd (NSE: LAURUSLABS, BSE: 540222) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,06,442 Cr, it ranks #95 by market cap among the 6,189 Indian listed companies on FinBizNet, and #4 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,058.90 (as of 26 Oct 2026), the share price is 1.4% below its 52-week high of ₹2,089.00 and 124.3% above its 52-week low of ₹917.95. The share price is up 128.8% over one year and up 20.2% over three months.
| Current Price | ₹2,058.90 |
|---|---|
| Market Cap | ₹1,06,442 Cr |
| NSE Symbol | LAURUSLABS |
| BSE Code | 540222 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| Return on Equity | 17.74% |
| Return on Assets | 8.18% |
| 52-Week Range | ₹917.95 – ₹2,089.00 |
| 1-Year Price Change | +128.8% |
| 3-Month Price Change | +20.2% |
| Beta (1Y) | 0.53 |
| Headquarters | Hyderabad, Telangana |
| Website | www.lauruslabs.com |
| Revenue | ₹2,026 Cr |
|---|---|
| Net Profit | ₹362 Cr |
| Net Margin | 17.9% |
| EPS (Basic) | ₹6.81 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
1. Manufacture of Active Pharmaceutical Ingredients, Intermediates and Formulations-This segment engages in the manufacture of active pharmaceutical ingredients, intermediates, and formulations. 2. Infosystems-This segment engages in the production and development of Internet programs, products, services, and applications. 3. Corporate-0
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,19,404 Cr | — | 14.72% | ₹15,300 Cr | +3.6% |
| Zydus Lifesciences Ltd | ₹1,12,658 Cr | — | 18.32% | ₹8,017 Cr | +17.5% |
| Cipla Limited | ₹1,08,090 Cr | — | 11.74% | ₹7,119 Cr | -14.1% |
| Laurus Labs Ltd | ₹1,06,442 Cr | — | 17.74% | ₹2,026 Cr | +128.8% |
| Dr.Reddys Lab | ₹1,02,010 Cr | — | 11.52% | ₹8,698 Cr | +4.4% |
| Mankind Pharma | ₹91,379 Cr | — | 12.45% | ₹4,031 Cr | -6.6% |
| Aurobindo Pharma Ltd. | ₹90,432 Cr | — | 9.93% | ₹9,150 Cr | +43.7% |
| Lupin Ltd | ₹88,018 Cr | — | 26.91% | ₹8,277 Cr | +1.0% |
| Glenmark Pharmaceuticals Limited | ₹61,142 Cr | — | 14.07% | ₹4,018 Cr | +19.5% |
Listed by market capitalisation. Ratios are shown for context only.
Laurus Labs Ltd is trading at ₹2,058.90, with a market capitalisation of ₹1,06,442 Cr.
Laurus Labs Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Laurus Labs Ltd has a return on equity of 17.74%.
Laurus Labs Ltd is listed on the NSE under the symbol LAURUSLABS and on the BSE under the scrip code 540222.
Laurus Labs Ltd's share price is up 128.8% over one year and up 20.2% over three months. Its 52-week range is ₹917.95 to ₹2,089.00.
In Q1 FY27, Laurus Labs Ltd reported revenue of ₹2,026 Cr and net profit of ₹362 Cr, with basic EPS of ₹6.81 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.